Advent Venture Partners
Advent Life Sciences gears up for growth fund
Healthcare-focused strategies remain bright spot in otherwise dull fundraising market
Advent Life Sciences hires three partners
Dominic Schmidt is based in the UK, while Satish Jindal and Katrine Bosley join in the US
Advent Life Sciences raises $215m across two new funds
Funds invest in early- and mid-stage life sciences companies developing new therapeutics and technologies
Advent, Columbus lead €22.6m round for Highlight Therapeutics
Company intends to use the fresh capital to further develop its drug candidate BO-112
Novartis, Novo lead €9m series-A for Rappta Therapeutics
Round also saw participation from family office Advent Life Sciences, and Business Finland
VCs in £27m series-A for MiroBio
Advent Life Sciences, SR One, Oxford Science Innovation and Samsara Biocapital have invested
Longitude leads £25m Kandy Therapeutics series-C
Recently founded biotech company will advance its menopause drug to the testing phase
VC-backed Farfetch gears up for listing
Online fashion marketplace files a registration statement for an IPO on the New York exchange
Advent gears up for launch of third life sciences fund
VC makes investments in life sciences companies based in the UK, continental Europe and the US
Advent France Biotechnology holds €64.75m first close
Firm was launched in 2016 and targets early-stage companies in the life sciences sector
Advent and Medicxi lead £11m series-A for Capella
Round for London-based biotech firm saw participation from two VCs and Osage University Partners
French IPOs: Last chance saloon?
Despite a large number of French listings over the past 18 months, rocky performance could close the window
Mary Kerr joins Advent Life Sciences as operating partner
Kerr worked with GSK for 14 years
Gilde Healthcare et al. invest £10m in Levicept
Company will use the funding to carry out its first clinical study
Deal in focus: uniQure raises $91.8m in IPO
Netherlands-based uniQure’s debut on the Nasdaq marks one of the latest in a string of European venture capital-backed biotechs flocking to the US markets, but the lack of activity in Europe's public markets does not necessarily equate to a slowdown in...
VC-backed uniQure raises $91.8m in IPO
Venture capital-backed Dutch gene therapy company uniQure raised well above its original expectation in its listing on the Nasdaq, bagging $91.8m.
VC-backed uniQure files $75m IPO
Dutch gene therapy company uniQure, backed by several venture capital firms, plans on raising up to $75m in its IPO on the Nasdaq.
European venture: patience rewarded
Patience rewarded
Serena Capital leads £10m round for WorldStores
Serena Capital and existing backers Balderton Capital and Advent Venture Partners have jointly invested ТЃ10m in a series-C funding round for UK-based online retailer WorldStores.
Oxford Capital et al. in $3m Celoxica round
Oxford Capital Partners has led a $3m funding round for London-based ultra-low latency market data provider Celoxica.
Cisco buys venture-backed Ubiquisys for $310m
Small cells developer Ubiquisys, a portfolio company of Advent Venture Partners, Accel Partners and Atlas Venture, has been bought by US corporate Cisco for $310m.
Advent Venture appoints new operating partner
Advent Venture Partners has appointed Ian Nicholson as an operating partner in its life sciences team.
Ubiquisys raises a further $19m
UK-based 3G technology company Ubiquisys has raised $19m in an oversubscribed round from existing investors, as well as new Chinese investors Mobile Internet Capital and Nissay Capital.
Advent Life Sciences gets re-up for latest fund
Advent Life Sciences Fund I, a 2010 vintage venture vehicle managed by Advent Venture Partners, was reopened to accept a new commitment as well as increased investments from existing LPs.